BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CorMedix readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies CorMedix's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06822426-918@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Defencath / Neutrolin (Taurolidine/heparin): Phase 3 readout est. (
 NCT06822426)
DESCRIPTION:Defencath / Neutrolin (Taurolidine/heparin)\, phase 3.\nStudy: 
 Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line 
 Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Rec
 eiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)\
 nEstimated primary completion: January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/taurolidine-heparin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06822426
URL:https://assetmemo.bio/drug/taurolidine-heparin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
